Overview

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

Status:
Completed
Trial end date:
2016-09-06
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept